Re-challenge of immunotherapy in a lung cancer patient

A. Toffart (Pontcharra, France)

Source: Virtual Congress 2021 – Lung cancer grand round
Session: Lung cancer grand round
Session type: Grand round
Number: 2736

WebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Toffart (Pontcharra, France). Re-challenge of immunotherapy in a lung cancer patient. Virtual Congress 2021 – Lung cancer grand round

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Eosinophilia in lung cancer patients treated with immunotherapy
Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology
Year: 2019

Boosting immunotherapy in lung cancer 
Source: International Congress 2017 – ME9 Boosting immunotherapy in lung cancer
Year: 2017


Impact of antibiotics on immunotherapy response in lung cancer patients
Source: International Congress 2019 – Treatment of lung cancer
Year: 2019

Immunotherapies for lung cancer
Source: International Congress 2018 – ME12 Immunotherapies for lung cancer FULLY BOOKED
Year: 2018


Ras peptide-specific vaccination in patients with non-small cell lung cancer (NSCLC)
Source: Annual Congress 2006 - Lung cancer treatment
Year: 2006


ME9 Boosting immunotherapy in lung cancer
Source: Milan 2017 - Educational material
Year: 2017

Mianserin therapy in advanced lung cancer patients
Source: Eur Respir J 2002; 20: Suppl. 38, 367s
Year: 2002

The evaluation of lung cancer patients
Source: Eur Respir J 2005; 26: Suppl. 49, 323s
Year: 2005

Radiation therapy for augmenting the efficacy of immunotherapy in advanced non-small cell lung cancer: a case-controlled study
Source: ERJ Open Res, 6 (1) 00189-2019; 10.1183/23120541.00189-2019
Year: 2020



Impact of COPD on prognosis of lung cancer: the prespective of immunotherapy treatment
Source: Virtual Congress 2021 – Therapy of lung cancer
Year: 2021


Dealys in the diagnosis and treatment of lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 458s
Year: 2004

Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy
Source: Eur Respir J 2012; 39: 1437-1442
Year: 2012



Lung cancer immunotherapy
Source: International Congress 2018 – Imminent global problems in lung cancer require joint action: time for an international alliance!
Year: 2018


Chemotherapy for small cell lung cancer
Source: Annual Congress 2006 - PG12 - Small cell lung cancer management
Year: 2006


How to evaluate the immune status of lung cancer patients before immunotherapy
Source: Breathe, 13 (4) 291; 10.1183/20734735.001917
Year: 2017



Our experience with crizotinib in the treatment of non-small cell lung cancer
Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer
Year: 2020


Second-line therapy in elderly patients with advanced nonsmall cell lung cancer
Source: Eur Respir J 2014; 43: 240-249
Year: 2004



Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm
Source: Eur Respir J, 55 (2) 1901907; 10.1183/13993003.01907-2019
Year: 2020



Second-line treatment patients at relapse of disseminated small cell lung cancer
Source: Eur Respir J 2001; 18: Suppl. 33, 395s
Year: 2001

Possibility of the specific efficacy of gefitinib for miliary lung metastasis in non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 303s
Year: 2004